Answers are grounded in this paper and cite their sources.
Sepsis is a leading cause of mortality, and ferroptosis has been implicated in sepsis-associated organ injury. Dexmedetomidine (DEX), an α2-adrenergic agonist with anti-inflammatory properties, may modulate this process. We examined whether DEX protects against cecal ligation and puncture (CLP)– induced septic lung injury and alters ferroptosis-associated markers in rats. Thirty-two female Wistar rats were randomized to sham, CLP, and CLP pretreated with DEX (30–50 µg/kg, intraperitoneally, 30 min before CLP) groups ( n = 8 each) and euthanized 16 h after surgery. Lung injury was assessed histopathologically; ferroptosis and inflammation were evaluated by serum ELISA (MDA, ferritin, ACSL4, HO-1, IL-18, SLC7A11), immunohistochemistry (GPX4, TFRC), and immunofluorescence (AQP5, IL-1β). CLP produced severe lung injury, increased MDA, ferritin, ACSL4, HO-1, IL-18, TFRC, and IL-1β, and decreased SLC7A11, GPX4, and AQP5. DEX attenuated histopathological injury, with an ordered dose trend for the primary outcome (interstitial pneumonia; p < 0.001), and shifted these biomarkers toward sham; serum markers differed between doses, and normalization remained partial. These findings indicate that DEX mitigates CLP-induced lung injury, associated with reduced lipid peroxidation, iron-handling, and inflammatory markers, and partial restoration of SLC7A11 and GPX4; whether ferroptosis inhibition mediates this protection requires confirmation with ferroptosis inhibitors and inducers.
No takes yet. Share an insight, caveat, or question.
Fakirullahoğlu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: